'Improving the quality of life for all.'
Our vision is to eliminate as much pain and difficulty in everyday life as possible.
We are developing a device that can visualize pain and is small enough to be used in clinics as well as hospitals. Our goal is to develop a compact device that is easy to attach and detach, like a small electroencephalograph (EEG), and that will be widely used in the medical field with little burden on the patient.
We contribute to society by establishing a method to measure pain with a standardized index for everyone, in order to provide safe and comfortable medical care equally to patients.
In order to bring smiles back to the faces of pain sufferers all over the world, we keep progressing every day, first with our own smiles and then to bring happiness to everyone who supports us.
At PaMeLa, we conduct research to “visualize” pain, with the aim of lowering mean levels of pain experienced by people around the world.
Pain is a warning to the body, and accurately understanding pain is important for treatment and other purposes. However, there are currently challenges where patients self-report their pain subjectively and are unable to properly communicate the severity of their pain to their physicians, or are unable to express they are feeling pain at all.
This leads to social disadvantages, such as a decline in the patient's quality of life and an increase in medical costs, as the pain persists and chronic pain develops. Regarding our overseas expansion, there is a global need for methods to objectively evaluate pain, particularly in light of issues such as the opioid crisis in the United States.
Our company aims to solve these issues by “visualizing” pain with the help of artificial intelligence.
[Career Background]
Graduated from Nagoya University, Graduate School of Engineering. Master of Business Administration (MBA), Graduate School of Management, Tokyo Metropolitan University
After working as a researcher at a Japanese beverage manufacturer, joined at a consultation company, then served as a manager of the New Business Development and Intellectual Property Department of Sekisui Chemical, Co., Ltd. Assumed responsibility for funding domestic and overseas startups at a venture capital firm specialized in materials and chemicals,
and then served as external director/COO at two companies. After serving as COO at a biological startup, joined PaMeLa.
| Company Name | PaMeLa Inc. |
|---|---|
| Capital | 95.68 million JPY |
| Representative | Hiroaki Goto, President and CEO |
| Business | Marketing and Manufacturing of Medical Devices |
| Establishment | February 2016 |
| Location | 6F Hankyu Senri Chuo Building, 1-4-1 Shinsenri Higashimachi, Toyonaka, Osaka, 560-0082, JAPAN |
| Board of Directors | Corporate director Syosuke Kiba (Universal Materials Incubator Co., Ltd.) Corporate director Arata Hasegawa Corporate Auditor Akira Watanabe (Universal Materials Incubator Co., Ltd.) |
| Fiscal year end | July |
| Employees | 8 |
| Main Banks |
Sumitomo Mitsui Banking Corporation, SMBC Senshu Ikeda Bank, Ltd. , Mizuho Bank, Ltd., MUFG Bank, Ltd., The Bank of Kyoto, Ltd., JAPAN POST BANK Co., Ltd. |
| Access | 3-minute walk from Senri Chuo Station (Kita Osaka Kyuko) 6-minute walk from Senri Chuo Station (Osaka Monorail) 2-minute walk from Senri Chuo Station (Hankyu Bus) |
| Feb. 2016 | Established PRIN Inc. |
|---|---|
| Jul. 2018 | Changed trade name from PRIN Inc. to PaMeLa Inc. |
| May 2020 | Started exploratory trial |
| Jul. 2021 | Finished exploratory trial |
| Mar. 2024 | Started confirmatory clinical trial |
3-minute walk from Senri Chuo Station (Kita Osaka Kyuko)
6-minute walk from Senri Chuo Station (Osaka Monorail)
2-minute walk from Senri Chuo Station (Hankyu Bus)
